At NeonMind Biosciences, we believe in “mind over matter”.
Illuminating
and Healing
Your Mind
Illuminating and healing your mind
We plan to help people change their lives by changing their minds, through treatment with psychedelics.
01Our Focus
Psilocybin based treatments
Our first step is tackling one of the biggest health issues the world is facing right now: obesity.
Obesity accounts for
37%
of the global burden of disease.
NeonMind is exploring psilocybin (found in psychedelic mushrooms) as an innovative treatment approach to weight loss through a preclinical trial.
We know that psilocybin is known to activate serotonin receptors, and that serotonin can curb cravings, shut off appetite, and reduce eating.
Psilocybin based treatments
We are using our proprietary formulations to commercialize mushroom-infused functional food products.
Our NeonMind™ mushroom infused coffee commerce platform launched in November 2020 at www.neonmind.com and we are currently in revenues from direct to consumer sales of these products.
03Team
Scientific and Advisory
-
Chair, scientific advisory board- Dually boarded Neurologist and Psychiatrist and Canadian Institute of Health Research funded academic faculty member at the University of British Columbia.
- Completed a post doctoral fellowship at UBC and Harvard University.
- Maintains a research program in brain injury, mental health and addictions.
- Authored over 30 publications in the last 5 years.
- Founder and Director, Translational Life Sciences Inc. (of which NeonMind owns 18%).
-
Advisory Board Member and Consultant to Design Phase 2 Clinical Trial- Specialist in Internal Medicine, an Epidemiologist and Biostatistician, and a Professor of Psychiatry at UBC, where he was previously Professor of Internal Medicine,
- Expert in the treatment and study of eating and weight disorders and extensive experience in the design of clinical trials for treatments for eating disorders.
- Pioneered several new internationally recognized treatments and has more than 30 years of experience in eating disorder and obesity research and treatment and has 280 publications including 131 referenced articles, 23 invited chapters, and 9 books.
- Previously Head of General Internal Medicine at St. Paul’s Hospital and UBC, Head of the Obesity Clinic at St. Paul’s Hospital, Leader of the BC Eating Disorders Epidemiology Project in the Centre for Health Evaluation and Outcome Sciences, BC Provincial Director of Eating Disorders, and Medical Director of the Woodstone Residential Treatment Centre for Eating Disorders. He is a Member of the Brain Research Centre at UBC.
- Expertise includes eating disorders, anorexia nervosa, bulimia nervosa, binge eating disorder, avoidant/restrictive food intake disorder (ARFID), phobia, emetophobia, obesity, imaging of the brain using live 3D electrical brain scans, and treatment using live neurofeedback, vagus nerve stimulation and transcranial electrical stimulation.
-
Principal Investigator for the NeonMind Preclinical Trial- Tenured Faculty member at the Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, at the University of British Columbia.
- Authorized by Health Canada to possess psilocybin as the Principal Investigator for the NeonMind Preclinical Trial.
- Extensive experience working with controlled substances as part of his research.
- His doctoral and post-doctoral research involved a significant body of work using controlled substances.
- Maintains research programs based on a multidisciplinary and translational approach in both clinical and related preclinical research related to mental health and addictions.
-
Member, Advisory Board- Over 18 years of experience as a patent lawyer in the preparation and prosecution of patent applications in a variety of industries including: biotechnology, chemistry, biofuel, oil and gas and pharmaceuticals.
- In addition to designing and filing patent applications, Charles provides his clients with IP due diligence, validity, and freedom to operate opinions.
- Experience drafting and negotiating license agreements and advises on food and drug regulatory law, including product labelling and advertising.
-
Advisory Board Member- Professor of Psychology at Ryerson University, affiliate scientist at the Toronto Rehabilitation Institute, core member of the McMaster Institute for Music and the Mind (MIMM), adjunct professor at the University of Toronto’s Music and Health Collaboratory (MaHRC).
- Runs the Science of Music Auditory Research and Technology (SMART) Lab at Ryerson, and conducts research on the biological, cognitive, and social-emotional bases of music and speech.
- Interdisciplinary research in perceptual science, cognitive science, emotion science, and neuroplasticity. He is a Fellow of the Canadian Psychological Association and Massey College, and is a past president of the Canadian Acoustical Association.
- Recipient of numerous awards including 2012, Early Career Award, Canadian Soceity for Brain, Behaviour and Cognition, 2016, Early Career and Medal, International Commission for Acoustics (“for outstanding contribution to psychological acoustics, particularly the theory of musical cognition and perception)
- Hear the World Research Chair in Music and Emotional Speech from 2013 to 2019
- Almost 2,000 publications including 7 book chapters, 121 peer reviewed journal papers
-
Chair, scientific advisory board
- Dually boarded Neurologist and Psychiatrist and Canadian Institute of Health Research funded academic faculty member at the University of British Columbia.
- Completed a post doctoral fellowship at UBC and Harvard University.
- Maintains a research program in brain injury, mental health and addictions.
- Authored over 30 publications in the last 5 years.
- Founder and Director, Translational Life Sciences Inc. (of which NeonMind owns 18%).
Advisory Board Member and Consultant to Design Phase 2 Clinical Trial- Specialist in Internal Medicine, an Epidemiologist and Biostatistician, and a Professor of Psychiatry at UBC, where he was previously Professor of Internal Medicine,
- Expert in the treatment and study of eating and weight disorders and extensive experience in the design of clinical trials for treatments for eating disorders.
- Pioneered several new internationally recognized treatments and has more than 30 years of experience in eating disorder and obesity research and treatment and has 280 publications including 131 referenced articles, 23 invited chapters, and 9 books.
- Previously Head of General Internal Medicine at St. Paul’s Hospital and UBC, Head of the Obesity Clinic at St. Paul’s Hospital, Leader of the BC Eating Disorders Epidemiology Project in the Centre for Health Evaluation and Outcome Sciences, BC Provincial Director of Eating Disorders, and Medical Director of the Woodstone Residential Treatment Centre for Eating Disorders. He is a Member of the Brain Research Centre at UBC.
- Expertise includes eating disorders, anorexia nervosa, bulimia nervosa, binge eating disorder, avoidant/restrictive food intake disorder (ARFID), phobia, emetophobia, obesity, imaging of the brain using live 3D electrical brain scans, and treatment using live neurofeedback, vagus nerve stimulation and transcranial electrical stimulation.
-
Principal Investigator for the NeonMind Preclinical Trial
- Tenured Faculty member at the Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, at the University of British Columbia.
- Authorized by Health Canada to possess psilocybin as the Principal Investigator for the NeonMind Preclinical Trial.
- Extensive experience working with controlled substances as part of his research.
- His doctoral and post-doctoral research involved a significant body of work using controlled substances.
- Maintains research programs based on a multidisciplinary and translational approach in both clinical and related preclinical research related to mental health and addictions.
Member, Advisory Board- Over 18 years of experience as a patent lawyer in the preparation and prosecution of patent applications in a variety of industries including: biotechnology, chemistry, biofuel, oil and gas and pharmaceuticals.
- In addition to designing and filing patent applications, Charles provides his clients with IP due diligence, validity, and freedom to operate opinions.
- Experience drafting and negotiating license agreements and advises on food and drug regulatory law, including product labelling and advertising.
-
Advisory Board Member
- Professor of Psychology at Ryerson University, affiliate scientist at the Toronto Rehabilitation Institute, core member of the McMaster Institute for Music and the Mind (MIMM), adjunct professor at the University of Toronto’s Music and Health Collaboratory (MaHRC).
- Runs the Science of Music Auditory Research and Technology (SMART) Lab at Ryerson, and conducts research on the biological, cognitive, and social-emotional bases of music and speech.
- Interdisciplinary research in perceptual science, cognitive science, emotion science, and neuroplasticity. He is a Fellow of the Canadian Psychological Association and Massey College, and is a past president of the Canadian Acoustical Association.
- Recipient of numerous awards including 2012, Early Career Award, Canadian Soceity for Brain, Behaviour and Cognition, 2016, Early Career and Medal, International Commission for Acoustics (“for outstanding contribution to psychological acoustics, particularly the theory of musical cognition and perception)
- Hear the World Research Chair in Music and Emotional Speech from 2013 to 2019
- Almost 2,000 publications including 7 book chapters, 121 peer reviewed journal papers
-
Chair, scientific advisory board
- Dually boarded Neurologist and Psychiatrist and Canadian Institute of Health Research funded academic faculty member at the University of British Columbia.
- Completed a post doctoral fellowship at UBC and Harvard University.
- Maintains a research program in brain injury, mental health and addictions.
- Authored over 30 publications in the last 5 years.
- Founder and Director, Translational Life Sciences Inc. (of which NeonMind owns 18%).
Advisory Board Member and Consultant to Design Phase 2 Clinical Trial- Specialist in Internal Medicine, an Epidemiologist and Biostatistician, and a Professor of Psychiatry at UBC, where he was previously Professor of Internal Medicine,
- Expert in the treatment and study of eating and weight disorders and extensive experience in the design of clinical trials for treatments for eating disorders.
- Pioneered several new internationally recognized treatments and has more than 30 years of experience in eating disorder and obesity research and treatment and has 280 publications including 131 referenced articles, 23 invited chapters, and 9 books.
- Previously Head of General Internal Medicine at St. Paul’s Hospital and UBC, Head of the Obesity Clinic at St. Paul’s Hospital, Leader of the BC Eating Disorders Epidemiology Project in the Centre for Health Evaluation and Outcome Sciences, BC Provincial Director of Eating Disorders, and Medical Director of the Woodstone Residential Treatment Centre for Eating Disorders. He is a Member of the Brain Research Centre at UBC.
- Expertise includes eating disorders, anorexia nervosa, bulimia nervosa, binge eating disorder, avoidant/restrictive food intake disorder (ARFID), phobia, emetophobia, obesity, imaging of the brain using live 3D electrical brain scans, and treatment using live neurofeedback, vagus nerve stimulation and transcranial electrical stimulation.
Principal Investigator for the NeonMind Preclinical Trial- Tenured Faculty member at the Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, at the University of British Columbia.
- Authorized by Health Canada to possess psilocybin as the Principal Investigator for the NeonMind Preclinical Trial.
- Extensive experience working with controlled substances as part of his research.
- His doctoral and post-doctoral research involved a significant body of work using controlled substances.
- Maintains research programs based on a multidisciplinary and translational approach in both clinical and related preclinical research related to mental health and addictions.
-
Member, Advisory Board
- Over 18 years of experience as a patent lawyer in the preparation and prosecution of patent applications in a variety of industries including: biotechnology, chemistry, biofuel, oil and gas and pharmaceuticals.
- In addition to designing and filing patent applications, Charles provides his clients with IP due diligence, validity, and freedom to operate opinions.
- Experience drafting and negotiating license agreements and advises on food and drug regulatory law, including product labelling and advertising.
Advisory Board Member- Professor of Psychology at Ryerson University, affiliate scientist at the Toronto Rehabilitation Institute, core member of the McMaster Institute for Music and the Mind (MIMM), adjunct professor at the University of Toronto’s Music and Health Collaboratory (MaHRC).
- Runs the Science of Music Auditory Research and Technology (SMART) Lab at Ryerson, and conducts research on the biological, cognitive, and social-emotional bases of music and speech.
- Interdisciplinary research in perceptual science, cognitive science, emotion science, and neuroplasticity. He is a Fellow of the Canadian Psychological Association and Massey College, and is a past president of the Canadian Acoustical Association.
- Recipient of numerous awards including 2012, Early Career Award, Canadian Soceity for Brain, Behaviour and Cognition, 2016, Early Career and Medal, International Commission for Acoustics (“for outstanding contribution to psychological acoustics, particularly the theory of musical cognition and perception)
- Hear the World Research Chair in Music and Emotional Speech from 2013 to 2019
- Almost 2,000 publications including 7 book chapters, 121 peer reviewed journal papers
Management and Board
-
President & Chief Executive Officer- Over 25 years of experience in the pharmaceutical industry
- Former President, CEO and a Director of Mind Medicine Inc. (NEO:MMED), a pioneer in psychedelic drug development, for four months, prior to Mind Medicine becoming the first psychedelics company to list on a stock exchange.
- For over two years was President & CEO of Cipher Pharmaceuticals Inc. (TSX:CPH), under his leadership the company was restored to positive EBITDA with the execution of 7 business development transactions to rapidly expand the product pipeline.
- At Watson Pharmaceuticals, led the integration of major M&A transactions including Warner Chilcott (~$5B global acquisition), Forest Laboratories (~$28B global acquisition) and Allergan (~$66B global acquisition).
- Commercial Development experience across numerous therapeutic areas including obesity, addiction, and neurologic disorders.
-
Independent Director- Over 30 years of general management experience.
- Previously the Global Chief Transformation Officer at Johnson & Johnson Consumer Companies (NYSE:JNJ).
- In his role as Johnson & Johnson Company Group Chairman for Consumer North America, Mr. Smith delivered new growth levers such as Beauty Special Ops and the OceanX partnership, and oversaw several strategic acquisitions including Vogue International LLC, La Lumière, and Neostrata.
- Launched several entrepreneurial initiatives including co-Founder and CEO of Paragon Vitamins and co-Founder & Partner at Ignite Ventures Studios.
-
Executive Chairman, Director, Founder- Serial entrepreneur with over two decades of experience building companies.
- Recognized in PROFIT Magazine's W100 most successful entrepreneurs and her private company was included in PROFIT 500 Fastest Growing companies in 2015 and 2016.
- Co-founder, President and CEO of Better Plant Sciences Inc. (CSE: PLNT, OTCQB:VEGGF), the majority shareholder of NeonMind, 3 years.
- Initial officer and director for 2 years of Merus Labs Inc. (TSX:MSL), a speciality pharmaceutical company focused on acquiring and optimizing legacy and growth products , which was acquired by Norgine B.V. for $342 million in 2017.
-
Chief Psychedelic Officer- Social-entrepreneur who has played a key role in advancing the psychedelic movement over the last eight years
- Since May 2018 he has been on the board of directors for the Multidisciplinary Association of Psychedelic Studies (MAPS) Canada, where he acted as Chair of the Board for over two years
- Currently a board member and co-founder of the Canadian Psychedelic Association
- From 2012 to 2017, Trevor was active as the founder and President of Liberty Root Therapy Inc., a business dedicated to healing and transformation by legally providing the plant medicine ibogaine to people with opiate use disorder
- Featured in the award-winning documentary 'DOSED' about using magic mushrooms and Iboga to heal addiction, anxiety and depression
-
CFO- CFO of Better Plant Sciences Inc. (CSE: PLNT, OTCQB:VEGGF), for close to 3 years.
- Serves as Chair of the Audit Committee for Datable Technology Corp. (TSXV: TTM), since May 2015.
- Previously served as CFO of Hanwei Energy Services Corp. (TSX: HE) from April 2007 to May 2018 where he managed all aspects of finance, banking, compliance, accounting, reporting, internal control, and supporting the board of directors in financial oversight.
- Previously served as Chair of the Governance Committee and member of the Audit Committee of Poydras Gaming Finance Corp. (TSXV: PYD), for close to 2 years.
- Designated CPA, CGA
-
Vice President, Corporate Development- Strong background in biopharma and healthcare services, with experience in product development, commercialization, and corporate development.
- Developed and successfully launched innovative medical services while working at LifeLabs, Canada's largest medical diagnostics provider, with a focus on client needs and improved outcomes.
- Extensive experience in biopharma including playing pivotal roles in licensing and mergers and acquisitions at Cipher Pharmaceuticals, and raising capital to support product development at Therapure Biopharma (now part of Resilience Biotechnologies).
-
Vice President, Sales- Seasoned sales broker bringing more than 15 years of sales experience in the health and wellness industry.
- Worked with distributors to grow a multitude of brands in the skincare, edible mushrooms and other wellness spaces, including Four Sigmatic, Mikei Red Reishi, Sun Warrior, Thursday Plantation, Lavido Skin Care, Love Chock, My Matcha Life, and Kosmea Skin Care.
- Founder and operator for close to 7 years of Naturally Amber, a boutique creative firm specializing in sales consulting, social media, content marketing, design, and marketing for natural health and wellness brands.
-
Independent Director- Over 15 years of experience practicing as a securities lawyer, and is currently a a shareholder (partner) at Owen Bird, a downtown Vancouver law firm.
- Experience in representing public companies and companies intending to go public on the TSX-V, the CSE and the OTC, with a practice focused on mergers and acquisitions, corporate finance and securities.
- Member of the Law Society of New Brunswick since 1997 and a member of the Law Society of British Columbia since 2005.
-
President & Chief Executive Officer
- Over 25 years of experience in the pharmaceutical industry
- Former President, CEO and a Director of Mind Medicine Inc. (NEO:MMED), a pioneer in psychedelic drug development, for four months, prior to Mind Medicine becoming the first psychedelics company to list on a stock exchange.
- For over two years was President & CEO of Cipher Pharmaceuticals Inc. (TSX:CPH), under his leadership the company was restored to positive EBITDA with the execution of 7 business development transactions to rapidly expand the product pipeline.
- At Watson Pharmaceuticals, led the integration of major M&A transactions including Warner Chilcott (~$5B global acquisition), Forest Laboratories (~$28B global acquisition) and Allergan (~$66B global acquisition).
- Commercial Development experience across numerous therapeutic areas including obesity, addiction, and neurologic disorders.
Independent Director- Over 30 years of general management experience.
- Previously the Global Chief Transformation Officer at Johnson & Johnson Consumer Companies (NYSE:JNJ).
- In his role as Johnson & Johnson Company Group Chairman for Consumer North America, Mr. Smith delivered new growth levers such as Beauty Special Ops and the OceanX partnership, and oversaw several strategic acquisitions including Vogue International LLC, La Lumière, and Neostrata.
- Launched several entrepreneurial initiatives including co-Founder and CEO of Paragon Vitamins and co-Founder & Partner at Ignite Ventures Studios.
-
Executive Chairman, Director, Founder
- Serial entrepreneur with over two decades of experience building companies.
- Recognized in PROFIT Magazine's W100 most successful entrepreneurs and her private company was included in PROFIT 500 Fastest Growing companies in 2015 and 2016.
- Co-founder, President and CEO of Better Plant Sciences Inc. (CSE: PLNT, OTCQB:VEGGF), the majority shareholder of NeonMind, 3 years.
- Initial officer and director for 2 years of Merus Labs Inc. (TSX:MSL), a speciality pharmaceutical company focused on acquiring and optimizing legacy and growth products , which was acquired by Norgine B.V. for $342 million in 2017.
Chief Psychedelic Officer- Social-entrepreneur who has played a key role in advancing the psychedelic movement over the last eight years
- Since May 2018 he has been on the board of directors for the Multidisciplinary Association of Psychedelic Studies (MAPS) Canada, where he acted as Chair of the Board for over two years
- Currently a board member and co-founder of the Canadian Psychedelic Association
- From 2012 to 2017, Trevor was active as the founder and President of Liberty Root Therapy Inc., a business dedicated to healing and transformation by legally providing the plant medicine ibogaine to people with opiate use disorder
- Featured in the award-winning documentary 'DOSED' about using magic mushrooms and Iboga to heal addiction, anxiety and depression
-
CFO
- CFO of Better Plant Sciences Inc. (CSE: PLNT, OTCQB:VEGGF), for close to 3 years.
- Serves as Chair of the Audit Committee for Datable Technology Corp. (TSXV: TTM), since May 2015.
- Previously served as CFO of Hanwei Energy Services Corp. (TSX: HE) from April 2007 to May 2018 where he managed all aspects of finance, banking, compliance, accounting, reporting, internal control, and supporting the board of directors in financial oversight.
- Previously served as Chair of the Governance Committee and member of the Audit Committee of Poydras Gaming Finance Corp. (TSXV: PYD), for close to 2 years.
- Designated CPA, CGA
Vice President, Corporate Development- Strong background in biopharma and healthcare services, with experience in product development, commercialization, and corporate development.
- Developed and successfully launched innovative medical services while working at LifeLabs, Canada's largest medical diagnostics provider, with a focus on client needs and improved outcomes.
- Extensive experience in biopharma including playing pivotal roles in licensing and mergers and acquisitions at Cipher Pharmaceuticals, and raising capital to support product development at Therapure Biopharma (now part of Resilience Biotechnologies).
-
President & Chief Executive Officer
- Over 25 years of experience in the pharmaceutical industry
- Former President, CEO and a Director of Mind Medicine Inc. (NEO:MMED), a pioneer in psychedelic drug development, for four months, prior to Mind Medicine becoming the first psychedelics company to list on a stock exchange.
- For over two years was President & CEO of Cipher Pharmaceuticals Inc. (TSX:CPH), under his leadership the company was restored to positive EBITDA with the execution of 7 business development transactions to rapidly expand the product pipeline.
- At Watson Pharmaceuticals, led the integration of major M&A transactions including Warner Chilcott (~$5B global acquisition), Forest Laboratories (~$28B global acquisition) and Allergan (~$66B global acquisition).
- Commercial Development experience across numerous therapeutic areas including obesity, addiction, and neurologic disorders.
Independent Director- Over 30 years of general management experience.
- Previously the Global Chief Transformation Officer at Johnson & Johnson Consumer Companies (NYSE:JNJ).
- In his role as Johnson & Johnson Company Group Chairman for Consumer North America, Mr. Smith delivered new growth levers such as Beauty Special Ops and the OceanX partnership, and oversaw several strategic acquisitions including Vogue International LLC, La Lumière, and Neostrata.
- Launched several entrepreneurial initiatives including co-Founder and CEO of Paragon Vitamins and co-Founder & Partner at Ignite Ventures Studios.
Executive Chairman, Director, Founder- Serial entrepreneur with over two decades of experience building companies.
- Recognized in PROFIT Magazine's W100 most successful entrepreneurs and her private company was included in PROFIT 500 Fastest Growing companies in 2015 and 2016.
- Co-founder, President and CEO of Better Plant Sciences Inc. (CSE: PLNT, OTCQB:VEGGF), the majority shareholder of NeonMind, 3 years.
- Initial officer and director for 2 years of Merus Labs Inc. (TSX:MSL), a speciality pharmaceutical company focused on acquiring and optimizing legacy and growth products , which was acquired by Norgine B.V. for $342 million in 2017.
-
Chief Psychedelic Officer
- Social-entrepreneur who has played a key role in advancing the psychedelic movement over the last eight years
- Since May 2018 he has been on the board of directors for the Multidisciplinary Association of Psychedelic Studies (MAPS) Canada, where he acted as Chair of the Board for over two years
- Currently a board member and co-founder of the Canadian Psychedelic Association
- From 2012 to 2017, Trevor was active as the founder and President of Liberty Root Therapy Inc., a business dedicated to healing and transformation by legally providing the plant medicine ibogaine to people with opiate use disorder
- Featured in the award-winning documentary 'DOSED' about using magic mushrooms and Iboga to heal addiction, anxiety and depression
CFO- CFO of Better Plant Sciences Inc. (CSE: PLNT, OTCQB:VEGGF), for close to 3 years.
- Serves as Chair of the Audit Committee for Datable Technology Corp. (TSXV: TTM), since May 2015.
- Previously served as CFO of Hanwei Energy Services Corp. (TSX: HE) from April 2007 to May 2018 where he managed all aspects of finance, banking, compliance, accounting, reporting, internal control, and supporting the board of directors in financial oversight.
- Previously served as Chair of the Governance Committee and member of the Audit Committee of Poydras Gaming Finance Corp. (TSXV: PYD), for close to 2 years.
- Designated CPA, CGA
Vice President, Corporate Development- Strong background in biopharma and healthcare services, with experience in product development, commercialization, and corporate development.
- Developed and successfully launched innovative medical services while working at LifeLabs, Canada's largest medical diagnostics provider, with a focus on client needs and improved outcomes.
- Extensive experience in biopharma including playing pivotal roles in licensing and mergers and acquisitions at Cipher Pharmaceuticals, and raising capital to support product development at Therapure Biopharma (now part of Resilience Biotechnologies).
04Contact Us
Questions, Comments & Inquiries
We’d love to hear from you.
Please fill out the form below to submit a question, join our mailing list or request more information about the company.
Corporate Head Office
Investor Relations
Edge Communications
invest@neonmind.com
1-866-318-6874
transfer agent
Endeavor Trust Corporation
david@endeavortrust.com
604-559-8908
Media Inquiries
Exvera Communications Inc.
brittany@exvera.com
©2021 NeonMind Biosciences Inc.